CA2251353A1 - Dispositif pour administration transdermique de composes d'azapirone - Google Patents

Dispositif pour administration transdermique de composes d'azapirone

Info

Publication number
CA2251353A1
CA2251353A1 CA002251353A CA2251353A CA2251353A1 CA 2251353 A1 CA2251353 A1 CA 2251353A1 CA 002251353 A CA002251353 A CA 002251353A CA 2251353 A CA2251353 A CA 2251353A CA 2251353 A1 CA2251353 A1 CA 2251353A1
Authority
CA
Canada
Prior art keywords
azapirone
delivery device
transdermal delivery
transdermal
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002251353A
Other languages
English (en)
Other versions
CA2251353C (fr
Inventor
Cheryl M. Gentile
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aveva Drug Deliverty Systems Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to PCT/US1996/004745 priority Critical patent/WO1997037659A1/fr
Priority to CA002251353A priority patent/CA2251353C/fr
Priority to EP96912595A priority patent/EP0942727A1/fr
Priority to AU55363/96A priority patent/AU5536396A/en
Publication of CA2251353A1 publication Critical patent/CA2251353A1/fr
Application granted granted Critical
Publication of CA2251353C publication Critical patent/CA2251353C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA002251353A 1996-04-08 1996-04-08 Dispositif pour administration transdermique de composes d'azapirone Expired - Fee Related CA2251353C (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
PCT/US1996/004745 WO1997037659A1 (fr) 1996-04-08 1996-04-08 Dispositif pour administration transdermique de composes d'azapirone
CA002251353A CA2251353C (fr) 1996-04-08 1996-04-08 Dispositif pour administration transdermique de composes d'azapirone
EP96912595A EP0942727A1 (fr) 1996-04-08 1996-04-08 Dispositif pour administration transdermique de composes d'azapirone
AU55363/96A AU5536396A (en) 1996-04-08 1996-04-08 Transdermal delivery device for azapirone compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US1996/004745 WO1997037659A1 (fr) 1996-04-08 1996-04-08 Dispositif pour administration transdermique de composes d'azapirone
CA002251353A CA2251353C (fr) 1996-04-08 1996-04-08 Dispositif pour administration transdermique de composes d'azapirone

Publications (2)

Publication Number Publication Date
CA2251353A1 true CA2251353A1 (fr) 1997-10-16
CA2251353C CA2251353C (fr) 2008-10-07

Family

ID=25680592

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002251353A Expired - Fee Related CA2251353C (fr) 1996-04-08 1996-04-08 Dispositif pour administration transdermique de composes d'azapirone

Country Status (3)

Country Link
EP (1) EP0942727A1 (fr)
CA (1) CA2251353C (fr)
WO (1) WO1997037659A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0306859D0 (en) * 2003-03-25 2003-04-30 Arachnova Therapeutics Ltd Topical formulation and use of buspirone
JP6180520B2 (ja) * 2012-07-05 2017-08-16 エスケー ケミカルス カンパニー リミテッド ロチゴチンを含有した経皮吸収製剤（Ｔｒａｎｓｄｅｒｍａｌｃｏｍｐｏｓｉｔｉｏｎｃｏｍｐｒｉｓｉｎｇｒｏｔｉｇｏｔｉｎｅ）

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL91451A0 (en) * 1988-08-30 1990-04-29 Bristol Myers Co Pharmaceutical compositions comprising azapiron compounds and their use in the treatment of addiction
JPH06505712A (ja) * 1990-11-28 1994-06-30 サノ・コーポレーシヨン タバコ中毒の処理方法および装置
CA2159091C (fr) * 1993-03-26 2006-12-19 Richard J. Sharpe Application topique et systemique de la buspirone ou de derives de celle-ci pour le traitement de conditions pathologiques associees aux reponses immunitaires
WO1995001167A2 (fr) * 1993-06-25 1995-01-12 Alza Corporation Incorporation d'un amide poly-n-vinylique a un systeme transdermique

Also Published As

Publication number Publication date
WO1997037659A1 (fr) 1997-10-16
EP0942727A1 (fr) 1999-09-22
CA2251353C (fr) 2008-10-07

Similar Documents

Publication Publication Date Title
IE790756L (en) Cerebral therapeutic agent
CA2181742A1 (fr) Reduction de l'irritation de la peau pendant l'administration de medicament par electrotransport
ES2001996A6 (es) Procedimiento para preparar composiciones farmaceuticas contra enfermedades cronicas de trasplante frente a hospedante y contra enfermedades de autoinmunidad.
NO962833D0 (no) Transdermalt preparat omfattende polyvinylpyrrolidin
TW376319B (en) Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
ITMI961152A0 (it) Composizione terapeutica per la somministrazione transdermica di un principio attivo estrogeno o progestinico o di loro miscele
HK1014881A1 (en) Epidural administration of therapeutic compounds with sustained rate of release
IE893840L (en) Use of acetyl d-carnitines for treating glaucoma
ZA928011B (en) Transdermal administration of melatonin.
UA66812C2 (uk) Препаративна форма лікарського засобу із регульованим вивільненням активної речовини
CA2251966A1 (fr) Administration transdermique de dextromethorphane servant d'agent antitussif
MX9504023A (es) Composicion farmaceutica y transdermicamente activa que contiene acido 5-aminolaevulinico y procedimiento para su preparacion.
WO1999061010A3 (fr) TRAITEMENT DE L'INFERTILITE PAR DES COMPOSES STIMULANT LA PRODUCTION D'AMPc, SEULS OU ASSOCIES A AU MOINS UN COMPOSE STIMULANT LA MEIOSE
EP0199117A3 (fr) Application thérapeutique du phosphocréatine
CA2251353A1 (fr) Dispositif pour administration transdermique de composes d'azapirone
EP0476711A3 (fr) Utilisation de 5-fluorouracile pour le traitement du SIDA
CA2394471A1 (fr) Agent antipruritique a usage externe
CA2091134A1 (fr) Agent therapeutique contre les risques d'avortement
WO1999056734A3 (fr) Systeme therapeutique transdermique pour administration de candesartan
CZ223199A3 (cs) Použití inhibitorů COMT nebo jejich farmaceuticky vhodných solí nebo esterů pro výrobu léčiva k prevenci diabetických vaskulárních dysfunkcí
AU7935887A (en) Therapeutic agent for the treatment of peptic ulcer disease
CA2182812A1 (fr) Composition pharmaceutique pour administration transdermique systemique contenant du morphine-6-glucoronide comme principe actif
WO1986006960A3 (fr) Utilisation de nicorandile ou de pinacidile dans le traitement de maladies vasculaires peripheriques
ATE169819T1 (de) (-)-metrifonat enthaltendes arzneimittel
MX9701606A (es) Terapia de combinacion para evitar la perdida osea-progesterona y agonistas de estrogeno.

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed